Phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC)

被引：0
|
作者：
Cheng, A. -L. [1 ]
Finn, R. S. [2 ]
Qin, S. [3 ]
Han, K. -H. [4 ]
Ikeda, K. [5 ]
Piscaglia, F. [6 ]
Baron, A. [7 ]
Park, J. -W. [8 ]
Han, G. [9 ]
Jassem, J. [10 ]
Blanc, J. F. [11 ]
Vogel, A. [12 ]
Komov, D. [13 ]
Evans, T. J. [14 ]
Lopez, C. [15 ]
Dutcus, C. [16 ]
Ren, M. [16 ]
Kraljevic, S. [17 ]
Tamai, T. [16 ]
Kudo, M. [18 ]
机构：
[1] Natl Taiwan Univ Hosp, Taipei, Taiwan
[2] UCLA Med Ctr, Geffen Sch Med, Santa Monica, CA USA
[3] Nanjing Bayi Hosp, Nanjing, Jiangsu, Peoples R China
[4] Yonsei Univ, Severance Hosp, Seoul, South Korea
[5] Toranomon Gen Hosp, Tokyo, Japan
[6] Univ Bologna, Bologna, Italy
[7] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA
[8] Natl Canc Ctr Korea, Goyang Si, South Korea
[9] Fourth Mil Med Univ, Xijing Hosp, Xian, Shaanxi, Peoples R China
[10] Med Univ Gdansk, Gdansk, Poland
[11] Univ Bordeaux, Bordeaux, France
[12] Hannover Med Sch, Hannover, Germany
[13] NN Blokhin Canc Res Ctr, Moscow, Russia
[14] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[15] Marques de Valdecilla Univ Hosp, Santander, Spain
[16] Eisai Inc, Woodcliff Lake, NJ USA
[17] Eisai Ltd, Hatfield, PA USA
[18] Kindai Univ, Fac Med, Osaka, Japan
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
'V720
引用
收藏
页码：211 / 211
页数：1
相关论文
共 50 条
  • [41] A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459.
    Sangro, Bruno
    Park, Joong-Won
    Dela Cruz, Christine Marie
    Anderson, Jeffrey
    Lang, Lixin
    Neely, Jaclyn
    Shaw, James W.
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [42] Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
    Li, Qi
    Cao, Mengran
    Yuan, Guosheng
    Cheng, Xiao
    Zang, Mengya
    Chen, Ming
    Hu, Xiaoyun
    Huang, Jing
    Li, Rong
    Guo, Yabing
    Ruan, Jian
    Chen, Jinzhang
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [43] HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND DISEASE SYMPTOMS IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH LENVATINIB (LEN) OR SORAFENIB (SOR)
    Vogel, A.
    Qin, S.
    Kudo, M.
    Hudgens, S.
    Yamashita, T.
    Yoon, J.
    Fartoux, L.
    Simon, K.
    Lopez, C.
    Sung, M.
    Dutcus, C.
    Kraljevic, S.
    Tamai, T.
    Grunow, N.
    Meier, G.
    Breder, V
    VALUE IN HEALTH, 2017, 20 (09) : A454 - A455
  • [44] Health-related quality of Life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR)
    Vogel, A.
    Qin, S.
    Kudo, M.
    Hudgens, S.
    Yamashita, T.
    Yoon, J-H.
    Fartoux, L.
    Simon, K.
    Lopez Lopez, C.
    Sung, M.
    Dutcus, C.
    Kraljevic, S.
    Tamai, T.
    Grunow, N.
    Meier, G.
    Breder, V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [45] Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
    Su, Dan
    Wu, Bin
    Shi, Lizheng
    JAMA NETWORK OPEN, 2021, 4 (02)
  • [46] Phase II study of transhepatic artery chemoembolization (TACE) combined with tislelizumab (TIS) and lenvatinib (LEN) in patients with unresectable hepatocellular carcinoma(uHCC)
    Nong, X.
    Xie, J-L.
    Zhang, Y-M.
    Liang, J-C.
    Pan, Z-L.
    Zhang, Z-M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S871 - S871
  • [47] IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC).
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Kim, Tae-You
    Kudo, Masatoshi
    Lim, Ho Yeong
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed
    Li, Daneng
    Feng, Yin-Hsun
    Verret, Wendy
    Nicholas, Alan
    Li, Lindong
    Ma, Ning
    Zhu, Andrew X.
    Cheng, Ann-Lii
    CANCER RESEARCH, 2021, 81 (13)
  • [48] IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Mertens, Joachim
    Kim, Tae-You
    Kudo, Masatoshi
    Lim, Ho Yeong
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed
    Li, Daneng
    Feng, Yin-Hsun
    Verret, Wendy
    Nicholas, Alan
    Li, Lindong
    Ma, Ning
    Zhu, Andrew X.
    Cheng, Ann-Lii
    SWISS MEDICAL WEEKLY, 2021, 151 : 25 - 26
  • [49] Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.
    Vogel, Arndt
    Chan, Stephen Lam
    Ren, Zhenggang
    Bai, Yuxian
    Gu, Shanzhi
    Lin, Xiaoyan
    Chen, Zhendong
    Jia, Weidong
    Jin, Yongdong
    Guo, Yabing
    Hu, Xiaohua
    Sultanbaev, Alexander Valerievich
    Pazgan-Simon, Monika
    Pisetska, Margaryta
    Nip, Tsz Keung
    Zhang, Haisong
    Du, Jinghua
    Cheng, Ann-Lii
    Kaseb, Ahmed Omar
    Qin, Shukui
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Updated efficacy and safety results from a phase 1b study of the PD-1 antagonist CS1003 combined with lenvatinib (LEN) as first-line (1L) treatment in Chinese patients (pts) with unresectable hepatocellular carcinoma (uHCC).
    Shen, Lin
    Guo, Ye
    Zhang, Yanqiao
    Li, Wei
    Gong, Jifang
    Li, Qun
    Ma, Zhigang
    Wang, Nanya
    Su, Rila
    Cai, Zhongheng
    Guo, Rong
    Li, Peiqi
    Tse, Archie N.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16191 - E16191
12345